When is Daratumumab's Patent Set to Expire in India?
Daratumumab, a medication used to treat multiple myeloma, has patent protection in India that is anticipated to expire around 2030. However, the exact expiry date can be subject to legal challenges and extensions.
What is Daratumumab Used For?
Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of myeloma cells. It is approved for the treatment of certain types of multiple myeloma, an incurable blood cancer [1].
How Does Daratumumab Work?
The drug works by binding to CD38 on myeloma cells, triggering the immune system to attack and destroy them. It can also directly cause myeloma cells to die through various mechanisms [1].
Are There Any Biosimilar Versions of Daratumumab in Development for India?
Information regarding specific biosimilar development for India is not readily available. The development and approval of biosimilars are complex processes that depend on patent expiry, regulatory pathways, and manufacturing capabilities. Companies often seek to launch biosimilars once primary patents expire, but the landscape can be influenced by secondary patents and litigation.
What Are the Potential Risks and Side Effects of Daratumumab?
Common side effects associated with daratumumab treatment can include infusion-related reactions, fatigue, nausea, diarrhea, constipation, fever, and low blood counts [1]. More serious side effects may also occur.
Who Manufactures Daratumumab?
Daratumumab is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1].
Where Can I Find More Information on Daratumumab Patents in India?
For detailed information on drug patent expiry dates in India, including daratumumab, resources like DrugPatentWatch.com can provide comprehensive data and analysis [2].
Sources
[1] https://www.janssen.com/our-products/daratumumab
[2] https://drugpatentwatch.com